SATUDORA HOLDINGS CO., LTD. (JP:3544)
:3544
Want to see JP:3544 full AI Analyst Report?
Top Page
SATUDORA HOLDINGS CO., LTD.
(3544)
Select Model
Select Model
Rating:69Neutral
Price Target:
¥890.00
▲(8.67% Upside)
Action:Reiterated
Date:05/15/26
The score is driven mainly by strong financial performance (fast revenue growth and improving operating margins) and reasonable valuation (P/E 12.70). These positives are offset by weaker technicals, with the stock trading below key moving averages and showing overbought momentum signals (RSI/Stoch), which increases near-term downside risk.
Positive Factors
Revenue Growth
A 36.34% revenue increase signals sustained consumer demand and effective sales execution across its drugstore network. Robust top-line expansion strengthens the firm's ability to reinvest in stores, inventory and private brands, supporting durable scale advantages.
Negative Factors
High Leverage
Persistently elevated debt-to-equity, despite slight improvement, means higher interest obligations and constrained financial flexibility. Elevated leverage limits capacity for strategic investments and increases vulnerability to margin compression or slower sales periods.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
A 36.34% revenue increase signals sustained consumer demand and effective sales execution across its drugstore network. Robust top-line expansion strengthens the firm's ability to reinvest in stores, inventory and private brands, supporting durable scale advantages.
Read all positive factors
SATUDORA HOLDINGS CO., LTD. (3544) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥11.46B
Dividend Yield1.24%
Average Volume (3M)29.60K
Price to Earnings (P/E)20.8
Beta (1Y)0.28
Revenue Growth1.28%
EPS Growth-20.91%
CountryJP
Employees1,107
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)52.77
Shares Outstanding14,236,564
10 Day Avg. Volume15,720
30 Day Avg. Volume29,603
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.19
Price to Sales (P/S)0.12
P/FCF Ratio8.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SATUDORA HOLDINGS CO., LTD. Business Overview & Revenue Model
Company Description
Satudora Holdings Co., Ltd. is a Japanese enterprise primarily focused on operating drugstores and dispensing pharmacies. Its business operations are structured into two main divisions: Retail Business and IT Solution Business. Beyond its core ret...
How the Company Makes Money
The company makes money mainly by selling products through its drugstore retail network. Its core revenue stream is retail sales across multiple merchandise categories, typically including prescription and over-the-counter medicines (where permitt...
SATUDORA HOLDINGS CO., LTD. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
65
Positive
Cash Flow
72
Positive
| Breakdown | TTM | May 2024 | May 2023 | May 2022 | May 2021 | May 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 100.56B | 100.17B | 95.52B | 87.48B | 82.91B | 83.24B |
| Gross Profit | 25.82B | 24.29B | 22.31B | 20.03B | 18.89B | 19.38B |
| EBITDA | 3.04B | 3.06B | 2.71B | 1.58B | 1.95B | 1.81B |
| Net Income | 732.00M | 768.00M | 470.00M | 87.00M | 317.00M | 575.00M |
Balance Sheet | ||||||
| Total Assets | 46.90B | 46.45B | 45.14B | 43.28B | 41.59B | 38.48B |
| Cash, Cash Equivalents and Short-Term Investments | 3.05B | 2.67B | 2.67B | 2.31B | 2.96B | 2.66B |
| Total Debt | 15.00B | 17.21B | 17.39B | 18.11B | 13.88B | 12.00B |
| Total Liabilities | 37.05B | 36.52B | 35.90B | 34.44B | 32.70B | 29.80B |
| Stockholders Equity | 9.72B | 9.80B | 9.13B | 8.73B | 8.80B | 8.63B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.32B | 2.10B | -3.81B | -602.00M | 1.26B |
| Operating Cash Flow | 0.00 | 2.60B | 3.54B | -1.77B | 1.28B | 3.37B |
| Investing Cash Flow | 0.00 | -1.67B | -1.92B | -2.87B | -2.23B | 1.20B |
| Financing Cash Flow | 0.00 | -935.00M | -1.26B | 4.00B | 1.27B | -3.39B |
SATUDORA HOLDINGS CO., LTD. Technical Analysis
Positive
819.00
Price Trends
843.67
Negative
842.69
Negative
825.72
Positive
Market Momentum
-4.68
Negative
47.92
Neutral
51.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3544, the sentiment is Positive. The current price of 819 is below the 20-day moving average (MA) of 827.01, below the 50-day MA of 843.67, and below the 200-day MA of 825.72, indicating a neutral trend. The MACD of -4.68 indicates Negative momentum. The RSI at 47.92 is Neutral, neither overbought nor oversold. The STOCH value of 51.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3544.
SATUDORA HOLDINGS CO., LTD. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ¥11.46B | 20.80 | ― | 1.24% | 1.28% | -20.91% | |
68 Neutral | ¥453.08B | 14.43 | 11.37% | 3.04% | 5.08% | 2.07% | |
67 Neutral | ¥359.80B | 18.59 | ― | 0.41% | 14.59% | 7.84% | |
66 Neutral | ¥554.87B | 11.93 | 15.71% | 0.96% | 15.07% | 72.98% | |
62 Neutral | ¥923.65B | 22.33 | ― | 1.72% | ― | ― | |
60 Neutral | ¥482.85B | 15.32 | ― | 0.93% | 6.74% | 6.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:3544
SATUDORA HOLDINGS CO., LTD.
830.00
-11.65
-1.38%
JP:9989
Sundrug Co
3,875.00
-377.31
-8.87%
JP:7649
Sugi Holdings Co
2,944.00
-148.41
-4.80%
JP:3391
TSURUHA Holdings
2,053.00
-155.82
-7.05%
JP:3349
COSMOS Pharmaceutical Corporation
6,066.00
-2,649.65
-30.40%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,763.00
318.59
9.25%
SATUDORA HOLDINGS CO., LTD. Corporate Events
Satudora Holdings Warns of Sharper Profit Drop Despite Steady Sales and Higher Dividend
Mar 19, 2026
Satudora Holdings reported consolidated net sales of ¥75.9 billion for the nine months to February 15, 2026, essentially flat year on year, while operating profit fell 27.7% to ¥932 million and profit attributable to owners of parent dro...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.